Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Phase I: will look at different dose levels and regimens of everolimus combined with weekly
trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast
cancer.
Phase II: will assess the efficacy and safety of the 10mg daily dose of everolimus combined
with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing
metastatic breast cancer.